Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

NCT05132777 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer
EGFR Exon20 Insertion Mutations

Interventions

DRUG: JMT101
DRUG: Osimertinib Mesylate Tablets

Sponsor

Shanghai JMT-Bio Inc.

Collaborators

[object Object]